BHVN — Biohaven Ltd.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1935979 ·
Last close
$11.93
Market Cap
$1.80B
52W High
$18.57
52W Low
$7.48
ADV30
2,933,695
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -124,899,000 | -137,311,000 | 370,739,000 | 238,033,000 | 358,517,000 |
| Mar 2026 | 0 | — | -130,428,000 | -130,532,000 | 466,406,000 | 273,074,000 | 336,906,000 |
| Dec 2025 | 0 | — | -142,734,000 | -145,555,000 | 451,447,000 | 229,957,000 | 399,375,000 |
| Sep 2025 | 0 | — | -169,382,000 | -173,443,000 | 409,123,000 | 184,847,000 | 426,283,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-594,232,000
Investing CF
$150,894,000
Financing CF
$617,764,000
CapEx
$-715,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.67
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,215,068,000
Inventory
—
Receivables
$2,597,000
ST Investments
$74,743,000
EBIT TTM
$-654,245,000
Pretax Income TTM
$-646,572,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -745,378,000 | -738,822,000 | 451,447,000 | 399,375,000 | 52,072,000 | -609,438,000 |
| Dec 2024 | 0 | -885,111,000 | -846,422,000 | 615,107,000 | 191,671,000 | 423,436,000 | -582,453,000 |
| Dec 2023 | 0 | -436,051,000 | -408,168,000 | 513,212,000 | 85,237,000 | 427,975,000 | -331,725,000 |
| Dec 2022 | 0 | -567,932,000 | -570,279,000 | 661,783,000 | 123,012,000 | 538,771,000 | -297,689,000 |
TTM Snapshot
Revenues TTM
$751,872,000
NetIncome TTM
$-647,677,000
OpCashFlow TTM
—
Assets (Latest)
$466,406,000
Forward EPS
$-1.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | $1.81B | $36.98 | — |
| GENB | Generate Biomedicines, Inc. | $1.80B | $13.99 | — |
| ZYME | Zymeworks Inc. | $1.79B | $25.26 | — |
| XNCR | Xencor Inc | $1.82B | $24.50 | — |
| TRVI | Trevi Therapeutics, Inc. | $1.83B | $12.82 | — |
News headlines (Yahoo Finance, 1h cache)
Biohaven partners with Ono in $100m IgG degrader deal
2026-10-09 09:00 · Yahoo
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
2026-10-08 08:00 · Yahoo
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
2026-10-08 06:18 · Yahoo
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
2026-09-28 11:30 · Yahoo
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?
2026-09-25 21:08 · Yahoo
Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
2026-09-18 17:30 · Yahoo
Biohaven’s epilepsy drug hit with FDA clinical hold
2026-09-11 11:17 · Yahoo
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
2026-09-10 20:17 · Yahoo
FDA places partial hold on Biohaven’s epilepsy drug
2026-09-10 16:13 · Yahoo
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
2026-09-10 14:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.